Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of C. difficile, a causative agent for antibiotic-associated diarrhea from a hospital-acquired infection; foodborne products, such as tests for Enterohemorrhagic E. coli and Campylobacter jejuni; H. pylori to detect stomach ulcers; respiratory products; and women's health and sexually transmitted diseases Group B Streptococcu, Chlamydia trachomatis, Neisseria gonorrhea, and Herpes Simplex Virus Type 1 and Type 2. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded in 1976 and is headquartered in Cincinnati, Ohio.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:VIVO
CUSIP58958410
Phone513-271-3700
Debt
Debt-to-Equity Ratio0.27
Current Ratio5.41
Quick Ratio3.71
Price-To-Earnings
Trailing P/E Ratio25.30
Forward P/E Ratio23.80
P/E GrowthN/A
Sales & Book Value
Annual Sales$200.77 million
Price / Sales3.56
Cash Flow$1.0582 per share
Price / Cash15.97
Book Value$4.02 per share
Price / Book4.20
Profitability
EPS (Most Recent Fiscal Year)$0.67
Net Income$21.55 million
Net Margins8.42%
Return on Equity16.66%
Return on Assets11.38%
Miscellaneous
Employees640
Outstanding Shares42,340,000
Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions
What is Meridian Bioscience's stock symbol?
Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."
How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience?
Meridian Bioscience announced a quarterly dividend on Friday, April 27th. Stockholders of record on Monday, May 7th will be paid a dividend of $0.125 per share on Thursday, May 17th. This represents a $0.50 annualized dividend and a dividend yield of 2.96%. The ex-dividend date is Friday, May 4th. View Meridian Bioscience's Dividend History.
How were Meridian Bioscience's earnings last quarter?
Meridian Bioscience, Inc. (NASDAQ:VIVO) released its earnings results on Thursday, April, 26th. The company reported $0.21 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $0.21. The company earned $56.45 million during the quarter, compared to the consensus estimate of $55 million. Meridian Bioscience had a return on equity of 16.66% and a net margin of 8.42%. The firm's quarterly revenue was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.22 earnings per share. View Meridian Bioscience's Earnings History.
When is Meridian Bioscience's next earnings date?
What guidance has Meridian Bioscience issued on next quarter's earnings?
Meridian Bioscience issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share (EPS) guidance of $0.69-0.72 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.71. The company issued revenue guidance of $209-214 million, compared to the consensus revenue estimate of $210.55 million.
What price target have analysts set for VIVO?
1 equities research analysts have issued 12-month target prices for Meridian Bioscience's stock. Their predictions range from $16.00 to $16.00. On average, they anticipate Meridian Bioscience's stock price to reach $16.00 in the next year. View Analyst Ratings for Meridian Bioscience.
Who are some of Meridian Bioscience's key competitors?
Some companies that are related to Meridian Bioscience include Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Vermillion (VRML), ImmuCell (ICCC), Akers Biosciences (AKER), GeneNews (GNWSF) and Arca Biopharma (ABIO).
Who are Meridian Bioscience's key executives?
Meridian Bioscience's management team includes the folowing people:
- Mr. John A. Kraeutler, Exec. Chairman (Age 70)
- Ms. Melissa A. Lueke, Exec. VP, CFO, Principal Accounting Officer & Sec. (Age 55)
- Ms. Susan D. Rolih, Exec. VP of Global Regulatory & Quality Systems (Age 69)
- Mr. John P. Kenny, CEO & Director (Age 49)
- Mr. Lawrence J. Baldini, Exec. VP & Pres of Global Operations (Age 59)
Has Meridian Bioscience been receiving favorable news coverage?
Media headlines about VIVO stock have been trending somewhat positive on Friday, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Meridian Bioscience earned a media sentiment score of 0.07 on Accern's scale. They also assigned news headlines about the company an impact score of 47.03 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Meridian Bioscience's major shareholders?
Meridian Bioscience's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.72%), Dimensional Fund Advisors LP (4.30%), Systematic Financial Management LP (2.40%), Millennium Management LLC (1.98%), JPMorgan Chase & Co. (1.40%) and Schwab Charles Investment Management Inc. (1.34%). Company insiders that own Meridian Bioscience stock include Dwight E Ellingwood, John A Kraeutler, John Mccune Jr Rice, John Mcilwraith, Lawrence Baldini, Melissa Lueke, Richard Eberly and Vecheslav A Elagin. View Institutional Ownership Trends for Meridian Bioscience.
Which institutional investors are selling Meridian Bioscience stock?
VIVO stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Millennium Management LLC, Wells Fargo & Company MN, Spark Investment Management LLC, JPMorgan Chase & Co., Mondrian Investment Partners LTD, Russell Investments Group Ltd. and Cornercap Investment Counsel Inc.. View Insider Buying and Selling for Meridian Bioscience.
Which institutional investors are buying Meridian Bioscience stock?
VIVO stock was acquired by a variety of institutional investors in the last quarter, including LSV Asset Management, Systematic Financial Management LP, BlackRock Inc., Schwab Charles Investment Management Inc., GSA Capital Partners LLP, Susquehanna Fundamental Investments LLC, Hancock Holding Co. and Alambic Investment Management L.P.. Company insiders that have bought Meridian Bioscience stock in the last two years include Dwight E Ellingwood, John A Kraeutler, John Mccune Jr Rice, John Mcilwraith, Lawrence Baldini and Melissa Lueke. View Insider Buying and Selling for Meridian Bioscience.
How do I buy shares of Meridian Bioscience?
Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Meridian Bioscience's stock price today?
One share of VIVO stock can currently be purchased for approximately $16.90.
How big of a company is Meridian Bioscience?
Meridian Bioscience has a market capitalization of $711.38 million and generates $200.77 million in revenue each year. The company earns $21.55 million in net income (profit) each year or $0.67 on an earnings per share basis. Meridian Bioscience employs 640 workers across the globe.
How can I contact Meridian Bioscience?
Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700.
MarketBeat Community Rating for Meridian Bioscience (VIVO)
MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe VIVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
